Precigen (PGEN) Change in Cash (2012 - 2026)
Precigen (PGEN) posted quarterly Change in Cash of -$22.8 million for Q1 2026, up 3.01% year-over-year from -$22.1 million in Q1 2025, and down 243.0% quarter-over-quarter from $15.9 million in Q4 2025.
Analysis
Precigen (PGEN) Change in Cash (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Change in Cash for 15 consecutive years, with -$22.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Cash rose 3.01% year-over-year to -$22.8 million; the TTM figure through Mar 2026 stood at $1.4 million (up 112.17% YoY), while the FY2025 annual figure was $717000.0, down 96.69% from the prior year.
- Change in Cash retreated to -$22.8 million in Q1 2026 per PGEN's latest filing, from $15.9 million in the prior quarter.
- Across five years, Change in Cash topped out at $42.0 million in Q3 2022 and bottomed at -$43.3 million in Q4 2022.
- Historically, Change in Cash has averaged -$2.1 million across 5 years, with a median of -$2.5 million in 2023.
- On a YoY basis, Change in Cash climbed as much as 691.23% in 2022 and fell as far as 3758.5% in 2022.
- Precigen's Change in Cash stood at -$43.3 million in 2022, then soared by 94.25% to -$2.5 million in 2023, then surged by 292.68% to $4.8 million in 2024, then soared by 232.05% to $15.9 million in 2025, then slumped by 243.0% to -$22.8 million in 2026.
- Business Quant data shows PGEN's Change in Cash at -$22.8 million in Q1 2026, $15.9 million in Q4 2025, and $562000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -185.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 427.25 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -2.94 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.42 Mn |
| 10 | Precigen | 2.53 Bn | 2.53 Bn | 52.17 Mn | 8.85 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 8.85 Mn |
| Mar 31, 2026 | -22.75 Mn |
| Dec 31, 2025 | 15.91 Mn |
| Sep 30, 2025 | 562,000.00 |
| Jun 30, 2025 | 7.70 Mn |
| Mar 31, 2025 | -23.46 Mn |
| Dec 31, 2024 | 4.79 Mn |
| Sep 30, 2024 | 15.12 Mn |
| Jun 30, 2024 | -8.14 Mn |
| Mar 31, 2024 | 9.90 Mn |
| Dec 31, 2023 | -2.49 Mn |
| Sep 30, 2023 | -6.62 Mn |
| Jun 30, 2023 | -6.99 Mn |
| Mar 31, 2023 | -24.65 Mn |
| Dec 31, 2022 | -43.28 Mn |
| Sep 30, 2022 | 41.98 Mn |
| Jun 30, 2022 | 9.17 Mn |
| Mar 31, 2022 | -2.61 Mn |
| Dec 31, 2021 | 1.18 Mn |
| Sep 30, 2021 | 5.31 Mn |